Pfizer A4061070

Metastatic Renal Cell Cancer Registry (MaRCC Registry)

Study Status: Open to enrollment

Why is this study being done?
The primary goal of this prospective, observational Phase IV study is to understand the treatment of patients with mRCC in routine real-world clinical practice in the United States (US), including both community and academic treatment settings. The study will collect and assess information on the therapies used such as sequence and duration, the drivers of physician selection of particular agents, changes in therapy over time, and discontinuation of therapies. The study will also explore patient experience through collection of patient reported outcomes (PROs).

Who is eligible to participate? (sex, age, health status, other)
Patients must meet all of the criteria to be eligible for the inclusion in the study:

  • Age 18 or over
  • Diagnosis of metastatic renal cell cancer (mRCC) with no prior systemic therapy for mRCC. Surgery and radiation therapy are permitted. Prior neoadjuvant and adjuvant therapy for non-metastatic renal cell cancer are permitted. Patients currently not on therapy and being observed are permitted.
  • Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.

Exclusion Criteria:
Patients being treated for active malignancies other than mRCC are excluded, unless all systemic therapy was completed at least 3 months prior to enrollment.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Love + Medicine

Every day, Gundersen Health System delivers great medicine plus a little something extra—we call it Love + Medicine.

Share Your Story